Scholar Rock Holding (SRRK) Free Cash Flow (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Free Cash Flow came in at -$82.1 million in Q1 2026, down 4.04% year-on-year from -$85.6 million in Q1 2025, and down 8.75% quarter-over-quarter from -$75.5 million in Q4 2025.
Scholar Rock Holding (SRRK) Free Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Free Cash Flow history runs 10 years deep, the most recent figure standing at -$82.1 million for Q1 2026.
- On a quarterly basis, Free Cash Flow fell 4.04% year-over-year to -$82.1 million in Q1 2026; TTM through Mar 2026 was -$303.8 million, a 31.8% decrease from a year earlier, with the FY2025 full-year figure at -$300.6 million, down 49.54% from the prior year.
- Free Cash Flow retreated to -$82.1 million in Q1 2026 per SRRK's latest filing, from -$75.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$26.5 million in Q3 2022 and bottomed at -$82.1 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$49.5 million (2024), against an average of -$50.9 million.
- Across the five-year window, Free Cash Flow rose 29.03% in 2022 and slumped 61.87% in 2024, its largest moves.
- Year by year, Free Cash Flow stood at -$29.9 million in 2022, then slumped by 35.42% to -$40.4 million in 2023, then retreated by 24.2% to -$50.2 million in 2024, then sank by 50.4% to -$75.5 million in 2025, then decreased by 8.75% to -$82.1 million in 2026.
- Per Business Quant, the three latest SRRK Free Cash Flow figures stand at -$82.1 million (Q1 2026), -$75.5 million (Q4 2025), and -$69.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | -82.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.14 Mn |
| Mar 31, 2026 | -82.14 Mn |
| Dec 31, 2025 | -75.53 Mn |
| Dec 31, 2025 | -75.53 Mn |
| Sep 30, 2025 | -69.47 Mn |
| Sep 30, 2025 | -69.47 Mn |
| Jun 30, 2025 | -76.69 Mn |
| Jun 30, 2025 | -76.69 Mn |
| Mar 31, 2025 | -78.95 Mn |
| Mar 31, 2025 | -78.95 Mn |
| Dec 31, 2024 | -50.22 Mn |
| Dec 31, 2024 | -50.22 Mn |
| Sep 30, 2024 | -51.80 Mn |
| Sep 30, 2024 | -51.80 Mn |
| Jun 30, 2024 | -49.56 Mn |
| Jun 30, 2024 | -49.56 Mn |
| Mar 31, 2024 | -49.47 Mn |
| Mar 31, 2024 | -49.47 Mn |
| Dec 31, 2023 | -40.43 Mn |
| Dec 31, 2023 | -40.43 Mn |